RxDoctor Payments Data

Markeeta Araujo, APRN

Nurse Practitioner · Pahrump, NVNPI 1285106724

Payments from drug & device makers

$904in general payments, 2019–2025

Across 45 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lucid Diagnostics Inc.$393
  • AstraZeneca$179
  • Amgen$141
  • Merck$73
  • Novo Nordisk$52
  • Bayer$26
  • plus $41 from 2 others

What the payments were for

  • Food & beverage$904100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lucid Diagnostics Inc.21$393
AstraZeneca11$179
Amgen6$141
Merck1$73
Novo Nordisk3$52
Bayer1$26
AbbVie1$25
Exact Sciences1$16

How this compares

$904 in reported general payments places this provider in the 70th percentile of 933 nurse practitioner providers in Nevada.

See all nurse practitioner providers in Nevada

Medicare billing

Part B allowed, 2024
$125,712
Medicare patients
272
Services billed
1,990

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide125$148,743
EliquisApixaban57$65,412
MounjaroTirzepatide38$49,220
FarxigaDapagliflozin Propanediol30$35,643
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$34,807
JardianceEmpagliflozin21$29,641
LinzessLinaclotide12$17,035
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$11,815
Albuterol Sulfate HfaAlbuterol Sulfate167$7,355
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$4,204
Levothyroxine Sodium273$3,347
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$3,076
Novolog FlexpenInsulin Aspart27$2,931
Rosuvastatin Calcium152$2,855
Testosterone21$2,780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$52$148,743125 claims
AstraZenecaFarxiga, Breztri Aerosphere$179$70,45062 claims
AbbVieLinzess, Synthroid$25$18,11025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 933 nurse practitioner providers in Nevada.

Other nurse practitioner in Pahrump

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →